Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)

Archives of Biochemistry and Biophysics

Volumn 445, Issue 1, 2006, Pages 9-18

  Kim, Young B ^a   Kopcho, Lisa M ^a   Kirby, Mark S ^a   Hamann, Lawrence G ^a   Weigelt, Carolyn A ^a   Metzler, William J ^a   Marcinkeviciene, Jovita ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Covalent intermediate; Diabetes; Dipeptide cleavage; GLP 1; Human DPP IV; Mechanism of inhibition; Saxagliptin; Serine protease

Indexed keywords

AMINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME; ENZYME INHIBITOR; GLYCINE; PROLINE; SAXAGLIPTIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; COVALENT BOND; ENZYME ACTIVE SITE; ENZYME INHIBITION; FRACTIONATION; HYDROGEN BOND; IONIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STEADY STATE;

ADAMANTANE; ANTIGENS, CD26; CATALYSIS; DIPEPTIDES; ENZYME INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; SOLVENTS;

EID: 29244449635     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2005.11.010     Document Type: Article

References (42)

1. I. Schechter, and A. Berger On the size of the active site in proteases. I. Papain Biochem. Biophys. Res. Commun. 27 1967 157 162
2. J.J. Holst, C. Orskov, O.V. Nielsen, and T.W. Schwartz Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut FEBS Lett. 211 1987 169 174
3. C. Orskov, J.J. Holst, and O.V. Nielsen Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach Endocrinology 123 1988 2009 2013
4. T. Vilsboll, H. Agerso, T. Krarup, and J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J. Clin. Endocrinol. Metab. 88 2003 220 224
5. B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olson, H. Torgeirsson, P.A. Jansson, M. Sandquist, P. Bavenholm, S. Efendic, and J.W. Eriksson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869 875
6. W.G. Gutheil, and W.W. Bachovchin Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition Biochemistry 32 1993 8723 8731
7. H.-U. Demuth, D. Schlenzing, A. Schierhorn, G. Grosche, M.-P. Chapt-Chartier, and J.-C. Gripon Design of (omega-N-(O-acyl)hydroxy amid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases FEBS Lett. 320 1993 23 27
8. B. Boduszek, J. Oleksyszyn, C.-M. Kam, J. Selzler, R.E. Smith, and J.C. Powers Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV J. Med. Chem. 37 1994 3969 3976
9. J.-U. Peters, D. Hunziker, H. Fischer, M. Kansy, S. Weber, S. Kritter, A. Muller, A. Wallier, F. Ricklin, M. Boehringer, S.M. Poli, M. Csato, and B.-M. Loeffler Aminomethylpyridines as DPP-IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 3575 3578
10. E.R. Parmee, J. He, A. Mastracchio, S.D. Edmonson, L. Colwell, and G. Eiermann 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 43 46
11. H.B. Rasmussen, S. Branner, F.C. Wiberg, and N. Wagtmann Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog Nat. Struct. Biol. 10 2003 19 25
12. C. Oefner, A. D'Arcy, A. Mac Sweeney, S. Pierau, R. Gardiner, and G.E. Dale High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano- (S)- pyrrolidine Acta Cryst. D59 2003 1206 1211
13. K. Aertgeerts, S. Ye, M. Tennant, M. Kraus, J. Rogers, B. Sang, R. Skene, D. Webb, and G. Prasad Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation Protein Sci. 13 2004 412 421
14. R. Thoma, B. Loffler, M. Stihle, W. Huber, A. Ruf, and M. Henning Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV Structure 11 2003 947 959
15. T.E. Hughes, M.D. Mone, M.E. Russell, S.C. Weldon, and E.B. Villhauer NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV Biochemistry 38 1999 11597 11603
16. D.J. Augeri, D.A. Betebenner, D.R. Magnin, J.A. Robl, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, M.S. Kirby, R.A. Parker, and L.G. Hamann Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 5025 5037
17. L.M. Kopcho, Y.B. Kim, A. Wang, M.A. Liu, M.S. Kirby, and J. Marcinkeviciene Probing prime substrate binding sites of human dipeptidyl peptidase-IV using competitive substrate approach Arch. Biochem. Biophys. 436 2005 367 376
18. J.F. Morrison, and C.T. Walsh The behavior and significance of slow-binding enzyme inhibitors Adv. Enzymol. 61 1988 201 206
19. K.B. Schowen, and R.L. Schowen Solvent isotope effects of enzyme systems Methods Enzymol. 87 1982 551 606
20. W.W. Cleland Statistical analysis of enzyme kinetic data Methods Enzymol. 63 1979 103 138
21. P.J. Hore Solvent suppression in Fourier transform nuclear magnetic resonance J. Magn. Reson. 55 1983 283 300
22. J.L. Markley, and W.M. Westler Protonation-state dependence of hydrogen bond strengths and exchange rates in a serine protease catalytic triad: bovine chymotrypsinogen A Biochemistry 35 1996 11092 11097
23. S.N. Loh, and J.L. Markley Hydrogen bonding in proteins as studied by amide hydrogen D/H fractionation factors: application to staphylococcal nuclease Biochemistry 33 1994 1029 11097
24. A. Fersht Enzyme Structure and Mechanism 1997 W.H. Freeman and Company New York pp. 143-147
25. S.G. Waley The kinetics of substrate-induced inactivation Biochem. J. 279 1991 87 94
26. W.A. Escobar, A.K. Tan, E.R. Lewis, and A.L. Fink Site-directed mutagenesis of glutamate-166 in beta-lactamase leads to a branched path mechanism Biochemistry 33 1994 7619 7626
27. A.L. Fink, K.M. Behner, and A.K. Tan Kinetic and structural characterization of reversibly inactivated beta-lactamase Biochemistry 26 1987 4248 4258
28. D.G. Tew, H.F. Boyd, S. Ashman, C. Theobald, and C.A. Leach Mechanism of inhibition of LDL phospholipase A2 by monocyclic-beta-lactams. Burst kinetics and the effect of stereochemistry Biochemistry 37 1998 10087 10093
29. J.F. Morrison, and S.R. Stone Approaches to the study and analysis of the inhibition of enzymes by slow- and tight binding inhibitors Comments Mol. Cell. Biophys. 2 1985 347 368
30. J. Li, E. Wilk, and S. Wilk Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26) Arch. Biochem. Biophys. 323 1995 148 154
31. S. Zhong, K. Haghjoo, C. Kettner, and F. Jordan Proton magnetic resonance studies of the active center histidine of chymotrypsin complexed to peptideboronic acids:solvent accessibility to the Ns and Ne sites can differentiate slow-binding and rapidly reversible inhibitors J. Am. Chem. Soc. 117 1995 7048 7055
32. W.W. Bachovchin Confirmation of the assignment of the low-field proton resonance of serine proteases by using specifically nitrogen-15 labeled enzyme Proc. Natl. Acad. Sci. USA 82 1985 7948 7951
33. C.S. Cassidy, J. Lin, and P.A. Frey A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond Biochemistry 36 1997 4576 4584
34. B. Ahren, G. Pacini, J.E. Foley, and A. Schweizer Improved meal-related {beta}-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1year Diabetes Care 28 2005 1936 1940
35. B. Ahren, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 2004 2874 2888
36. M.L. Bender, G. Clement, J. Kezdy, and H. Heck The correlation of the pH (pD) dependence and the stepwise mechanism of a-chymotrypsin-catalyzed reactions J. Am. Chem. Soc. 86 1964 3680 3690
37. J.R. Bjelke, J. Christensen, S. Branner, S. Wagtmann, C. Olsen, A.B. Kanstrup, and H.B. Rasmussen Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV J. Biol. Chem. 279 2004 34691 34697
38. R.L. Stein, A.M. Strimpler, P.D. Edwards, J.J. Lewis, R.C. Mauger, J.A. Schwartz, M.M. Stein, A.D. Trainor, R.A. Wildonger, and M.A. Zottola Mechanism of slow-binding inhibition of human leukocyte elastase by trifluoromethyl ketones Biochemistry 26 1987 2682 2689
39. B. Thomas, Y. Wang, and R.L. Stein Kinetic and mechanistic studies of penicillin-binding protein 2x from Streptococcus pneumoniae Biochemistry 40 2001 15811 15823
40. D.M. Quinn, and L.D. Sutton Theoretical basis and mechanistic utility of solvent isotope effects P.F. Cook Enzyme Mechanisms from Isotope Effects 1991 CRC Press Boca Raton, Ann Arbor, Boston, London 73 126
41. G. Robillard, and R.G. Schulman High resolution nuclear magnetic resonance study of the histidine-aspartate hydrogen bond in chymotrypsin and chymotrypsinogen J. Mol. Biol. 71 1972 507 511
42. J. Lin, W.M. Westler, W.W. Cleland, J.L. Markley, and P.A. Frey Fractionation factors and activation energies for the low barrier hydrogen bonding proton in peptidyl trifluoromethylketone complexes of chymotrypsin Proc. Natl. Acad. Sci. USA 95 1998 14664 14668